PE20240780A1 - Formas cristalinas de un esteroide neuroactivo - Google Patents
Formas cristalinas de un esteroide neuroactivoInfo
- Publication number
- PE20240780A1 PE20240780A1 PE2024000161A PE2024000161A PE20240780A1 PE 20240780 A1 PE20240780 A1 PE 20240780A1 PE 2024000161 A PE2024000161 A PE 2024000161A PE 2024000161 A PE2024000161 A PE 2024000161A PE 20240780 A1 PE20240780 A1 PE 20240780A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- crystalline forms
- crystalline
- neuroactive steroid
- pharmaceutical compositions
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 230000000694 effects Effects 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invencion se relaciona con formas cristalinas del Compuesto anhidro (1) y composiciones farmaceuticas de estas. En particular, se refiere a una forma cristalina del Compuesto (1), en donde el Compuesto (1) esta representado por la formula estructural: Compuesto (1), y en donde la forma cristalina es el Compuesto anhidro cristalino (1). Tambien se describen metodos para producir formas solidas cristalinas del Compuesto (1), y metodos para utilizar las formas cristalinas del Compuesto (1) y composiciones farmaceuticas de estas para modular la actividad de GABA, por ejemplo, modulacion alosterica positiva de la actividad de GABA, y tratar los trastornos relacionados con el SNC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226374P | 2021-07-28 | 2021-07-28 | |
| PCT/US2022/038459 WO2023009584A1 (en) | 2021-07-28 | 2022-07-27 | Crystalline forms of a neuroactive steroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240780A1 true PE20240780A1 (es) | 2024-04-17 |
Family
ID=82932595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000161A PE20240780A1 (es) | 2021-07-28 | 2022-07-27 | Formas cristalinas de un esteroide neuroactivo |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11952397B2 (es) |
| EP (1) | EP4377327A1 (es) |
| JP (1) | JP2024527992A (es) |
| KR (1) | KR20240037975A (es) |
| CN (1) | CN117693516A (es) |
| AR (1) | AR126593A1 (es) |
| AU (1) | AU2022319712A1 (es) |
| BR (1) | BR112024001518A2 (es) |
| CA (1) | CA3226489A1 (es) |
| CL (1) | CL2024000217A1 (es) |
| CO (1) | CO2024000643A2 (es) |
| EC (1) | ECSP24007189A (es) |
| IL (1) | IL309922A (es) |
| MX (1) | MX2024001372A (es) |
| PE (1) | PE20240780A1 (es) |
| TW (1) | TW202320800A (es) |
| WO (1) | WO2023009584A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026337A1 (en) * | 2022-07-27 | 2024-02-01 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| ATE537748T1 (de) | 2002-10-15 | 2012-01-15 | Medtronic Inc | Medizinisches vorrichtungssystem zur bewertung von gemessenen neurologischen ereignissen |
| US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
| EP3572417A3 (en) | 2011-10-14 | 2020-03-25 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| ES2927007T3 (es) | 2014-05-29 | 2022-10-31 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PE20190915A1 (es) | 2016-08-23 | 2019-06-26 | Sage Therapeutics Inc | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino |
| BR112023021131A2 (pt) | 2021-04-12 | 2023-12-19 | Sage Therapeutics Inc | Tratamento de tremor essencial |
-
2022
- 2022-07-27 MX MX2024001372A patent/MX2024001372A/es unknown
- 2022-07-27 EP EP22755019.1A patent/EP4377327A1/en active Pending
- 2022-07-27 AU AU2022319712A patent/AU2022319712A1/en active Pending
- 2022-07-27 CN CN202280052002.8A patent/CN117693516A/zh active Pending
- 2022-07-27 CA CA3226489A patent/CA3226489A1/en active Pending
- 2022-07-27 PE PE2024000161A patent/PE20240780A1/es unknown
- 2022-07-27 WO PCT/US2022/038459 patent/WO2023009584A1/en active Application Filing
- 2022-07-27 BR BR112024001518A patent/BR112024001518A2/pt unknown
- 2022-07-27 KR KR1020247002865A patent/KR20240037975A/ko unknown
- 2022-07-27 IL IL309922A patent/IL309922A/en unknown
- 2022-07-27 JP JP2024505045A patent/JP2024527992A/ja active Pending
- 2022-07-28 AR ARP220102007A patent/AR126593A1/es unknown
- 2022-07-28 TW TW111128327A patent/TW202320800A/zh unknown
-
2023
- 2023-08-02 US US18/363,942 patent/US11952397B2/en active Active
-
2024
- 2024-01-25 CO CONC2024/0000643A patent/CO2024000643A2/es unknown
- 2024-01-25 CL CL2024000217A patent/CL2024000217A1/es unknown
- 2024-01-26 EC ECSENADI20247189A patent/ECSP24007189A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP24007189A (es) | 2024-02-29 |
| CL2024000217A1 (es) | 2024-08-23 |
| US20230374061A1 (en) | 2023-11-23 |
| CN117693516A (zh) | 2024-03-12 |
| US11952397B2 (en) | 2024-04-09 |
| KR20240037975A (ko) | 2024-03-22 |
| AR126593A1 (es) | 2023-10-25 |
| BR112024001518A2 (pt) | 2024-04-30 |
| TW202320800A (zh) | 2023-06-01 |
| IL309922A (en) | 2024-03-01 |
| AU2022319712A1 (en) | 2024-01-18 |
| EP4377327A1 (en) | 2024-06-05 |
| CA3226489A1 (en) | 2023-02-02 |
| JP2024527992A (ja) | 2024-07-26 |
| CO2024000643A2 (es) | 2024-02-05 |
| MX2024001372A (es) | 2024-02-27 |
| WO2023009584A1 (en) | 2023-02-02 |
| US20240218012A1 (en) | 2024-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240780A1 (es) | Formas cristalinas de un esteroide neuroactivo | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| ECSP23012042A (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| CO2022011194A2 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| CO2021000153A2 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| UY39390A (es) | Forma amorfa de un inhibidor de la malt1 y formulaciones del mismo | |
| AR127470A1 (es) | Inhibidores de lrrk2 | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| CL2022002368A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| AR116026A1 (es) | Composición para erradicar helicobacter pylori | |
| CL2021001640A1 (es) | Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo | |
| AR126215A1 (es) | Proceso novedoso | |
| CO2021005738A2 (es) | Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y métodos de uso | |
| UY38072A (es) | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos | |
| CO2021008043A2 (es) | Formas cristalinas de un inhibidor de par4 | |
| AR041219A1 (es) | Derivados de aminoacidos inhibidores de factor xa y otras serinaproteasas implicadas en la cascada de la coagulacion | |
| AR123228A1 (es) | Formas en estado sólido de un compuesto orgánico | |
| PE20230242A1 (es) | Composiciones farmaceuticas de sales de ester de colina de acido lipoico y metodos de tratamiento usando las mismas | |
| ECSP24007193A (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 | |
| CL2021000468A1 (es) | Tratamiento de trastornos hepáticos | |
| ECSP22030740A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |